KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera



Status:Recruiting
Conditions:Cancer, Hematology
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:18 - Any
Updated:4/3/2019
Start Date:January 15, 2019
End Date:October 2023
Contact:John Mei
Email:jmei@kartosthera.com
Phone:6505420136

Use our guide to learn which trials are right for you!

A Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera

This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the
treatment of patients with phlebotomy-dependent polycythemia vera (PV). Inhibition of MDM2 in
PV is a new mechanism of action in PV. In Part A, patients must be resistant or intolerant to
hydroxyurea or have undergone treatment with interferon. In Part B, patients must be
resistant or intolerant to hydroxyurea.

This study is a global, open-label Phase 2a/2b study to determine the efficacy and safety of
KRT-232. In Part A of the study, patients will be randomly assigned to 3 arms with 2
different doses and 2 different dosing schedules of KRT 232. In Part B of the study, patients
will be randomized either to treatment with KRT-232 administered at the recommended dose and
schedule from Part A or to treatment with ruxolitinib.


Inclusion Criteria:

- Confirmed diagnosis of PV (WHO 2016)

- ECOG ≤ 2

- Part A: patients with and without splenomegaly are eligible

- Part A: patients must be resistant or intolerant to hydroxyurea or have undergone
treatment with interferon

- Part B: only patients with splenomegaly are eligible

- Part B: patients must be resistant or intolerant to hydroxyurea

Exclusion Criteria:

- Diagnosis of post-PV myelofibrosis (IWG-MRT)

- Prior treatment with MDM2 inhibitors, p53-directed therapies, HDAC, BCL 2 inhibitors

- Splenic irradiation within 3 months prior to the first dose of study treatment

- Clinically significant thrombosis within 3 months of screening

- Grade 2 or higher QTc prolongation

- Part B: prior treatment with a JAK inhibitor
We found this trial at
9
sites
Florham Park, New Jersey 07932
?
mi
from
Florham Park, NJ
Click here to add this to my saved trials
3181 Southwest Sam Jackson Park Road
Portland, Oregon 97239
503 494-8311
Phone: 503-346-0227
Oregon Health and Science University In 1887, the inaugural class of the University of Oregon...
?
mi
from
Portland, OR
Click here to add this to my saved trials
Boynton Beach, Florida 33426
Phone: 561-737-6556
?
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
4875 Higbee Ave NW
Canton, Ohio 44718
330-492-3345
Gabrail Cancer Center Since 1990, Gabrail Cancer Center has built a national reputation for excellence...
?
mi
from
Canton, OH
Click here to add this to my saved trials
1801 West Taylor, Suite 1E
Chicago, Illinois 60612
312.355.1625
Phone: 312-996-5931
University of Illinois Cancer Center The University of Illinois Cancer Center is dedicated to reducing...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Hradec Králové,
Click here to add this to my saved trials
Los Angeles, California 90033
Phone: 323-865-3000
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Whittier, California 90603
Phone: 562-693-4477
?
mi
from
Whittier, CA
Click here to add this to my saved trials